<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099549</url>
  </required_header>
  <id_info>
    <org_study_id>AFM24-SNK01-103</org_study_id>
    <nct_id>NCT05099549</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers</brief_title>
  <official_title>A Phase 1/2a, Open-Label, Multi-Center Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With Ex Vivo Expanded Autologous Natural Killer Cells (SNK01) in Subjects With Advanced/Metastatic EGFR-Expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NKGen Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NKGen Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center study to evaluate the safety, tolerability, and&#xD;
      anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or&#xD;
      metastatic EGFR-expressing cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two phases. The Phase 1/dose escalation phase will gather&#xD;
      preliminary safety and tolerability data for escalating doses of AFM24 in combination with&#xD;
      SNK01 at a fixed dose in order to determine the MTD/RP2D for the combination dose regimen to&#xD;
      be used in the Phase 2a/expansion.&#xD;
&#xD;
      The Phase 2a/expansion portion of the study will gather additional safety, tolerability,&#xD;
      efficacy, and anti-tumor activity information for the combination of AFM24 with SNK01 in&#xD;
      subjects with three types of advanced or metastatic EGFR-expressing cancers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will be enrolled sequentially in cohorts of 3 to 6 subjects into Phase 1/dose escalation. The dose escalation will follow the standard oncology Phase 1 3 + 3 dose escalation design. A minimum of 3 cohorts will be utilized and dose increases will be determined by the Safety Review Committee.&#xD;
Once RP2D is determined in Phase 1/dose escalation, the Phase 2a/expansion phase will begin enrolling up to 121 subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Determine the maximum tolerated dose (MTD) of AFM24 in combination with SNK01. To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Determine the recommended phase 2 dose (RP2D) of AFM24 in combination with SNK01.&#xD;
To be assessed by the incidence and severity of dose-limiting toxicity (DLT) within the DLT observation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Determine objective response rate (ORR) of AFM24 in combination with SNK01. Determine ORR using Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Assess safety and tolerability of AFM24 in combination with SNK01. Determine frequency and severity of treatment-emergent AEs (TEAEs) per National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI CTCAE v 5.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Determine preliminary efficacy of AFM24 in combination with SNK01. Determine ORR using RECIST v1.1 evaluated by local assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of AFM24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of AFM24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Minimum plasma concentration (Cmin) of AFM24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1/Dose Escalation</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 anti drug antibodies (ADAs) through completion of the Phase 1/dose escalation portion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Safety and tolerability of AFM24 in combination with SNK01 Frequency of TEAEs graded according to NCI CTCAE v 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To assess progression-free survival (PFS) according to RECIST v1.1 by local assessment Assess the number of subjects with PFS defined as duration of time from start of combination treatment to date of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To assess overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To assess duration of response (DOR) according to RECIST v1.1 by local assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To assess clinical benefit rate (CBR) according to RECIST v1.1 by local assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of AFM24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Time to maximum plasma concentration (Tmax) of AFM24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Minimum plasma concentration (Cmin) of AFM24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>28 days starting on cycle 1 day 1</time_frame>
    <description>Area under plasma concentration-time curve for dosing interval (AUCtau) of AFM24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2a/Expansion</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Immunogenicity of AFM24 when AFM24 is given in combination with SNK01 Frequency of subjects developing AFM24 ADAs and frequency of subjects developing neutralizing ADAs.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">121</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Advanced Solid Tumor</condition>
  <condition>Refractory Tumor</condition>
  <condition>Metastatic Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1, Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is estimated that approximately 3-6 subjects will be enrolled per cohort in three dose cohorts for a total of 12-18 participants.&#xD;
SNK01 (fixed dose) will be administered weekly by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SNK01 (fixed dose) will be administered weekly by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SNK01 (fixed dose) will be administered weekly by IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SNK01 (fixed dose) will be administered weekly by IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFM24</intervention_name>
    <description>Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.</description>
    <arm_group_label>Phase 1, Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)</arm_group_label>
    <arm_group_label>Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)</arm_group_label>
    <arm_group_label>Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SNK01</intervention_name>
    <description>Patient-specific ex-vivo expanded autologous natural killer cells.</description>
    <arm_group_label>Phase 1, Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2a, Expansion Cohort 1 - Metastatic colorectal cancer (EXP-1: mCRC)</arm_group_label>
    <arm_group_label>Phase 2a, Expansion Cohort 2 - Head and Neck Squamous Cell Carcinoma (EXP-2: SCCHN)</arm_group_label>
    <arm_group_label>Phase 2a, Expansion Cohort 3 - Non-small cell lung cancer (EXP-3: NSCLC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Capable of giving signed informed consent&#xD;
&#xD;
          2. Males and females age ≥ 18 years&#xD;
&#xD;
          3. Phase 1/Dose Escalation : any histologically confirmed advanced or metastatic&#xD;
             EGFR-positive malignancy for which all standard of care treatment options have been&#xD;
             received and are no longer effective or are considered inappropriate at the discretion&#xD;
             of the investigator.&#xD;
&#xD;
          4. Phase 2a/Expansion : histologically confirmed advanced or metastatic EGFR positive&#xD;
             malignancy of mCRC (EXP-1 cohort), SCCHN (EXP-2 cohort) or NSCLC (EXP-3 cohort).&#xD;
&#xD;
          5. Additional Criteria for Phase 2a/Expansion: subjects must have a disease history&#xD;
             specific to their disease as listed below:&#xD;
&#xD;
               1. EXP-1: mCRC. Metastatic colorectal cancer (mCRC) MSI low/DNA mismatch repair&#xD;
                  proficient. Subjects must have received ≥ 1 lines of previous combination therapy&#xD;
                  and must have been exposed to oxaliplatin, irinotecan, a fluoropyrimidine, a VEGF&#xD;
                  targeting agent and, if considered appropriate by the treating physician, an EGFR&#xD;
                  targeted antibody.&#xD;
&#xD;
               2. EXP-2: SCCHN. Subjects with advanced or metastatic SCCHN whose disease has&#xD;
                  progressed after having received ≥ 1 prior lines of therapy for advanced disease,&#xD;
                  which must have included platinum-based therapy, fluoropyrimidine, and an anti PD&#xD;
                  1/PD-L1 antibody.&#xD;
&#xD;
               3. EXP-3: NSCLC. Subjects with advanced or metastatic EGFR-expressing NSCLC (EGFR&#xD;
                  WT) whose disease has progressed after having received ≥ 1 prior lines of therapy&#xD;
                  for advanced disease. Subjects must have received at least a platinum-based&#xD;
                  doublet in combination with anti-PD1/PD-L1 antibody or must have received a&#xD;
                  platinum-based doublet followed by an anti-PD1/PD-L1 antibody.&#xD;
&#xD;
          6. One or more measurable tumors lesions per RECIST v1.1&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          8. Adequate bone marrow, hepatic and renal function.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Superior vena cava syndrome contra-indicating hydration&#xD;
&#xD;
          2. Untreated or symptomatic central nervous system (CNS) metastases&#xD;
&#xD;
          3. No resolution of specific toxicities related to any prior anti-cancer therapy to Grade&#xD;
             ≤ 1 according to the NCI-CTCAE v.5.0 (except peripheral or motor neuropathy,&#xD;
             lymphopenia and alopecia)&#xD;
&#xD;
          4. Treatment with systemic anticancer therapy or an investigational device within 4 weeks&#xD;
             (6 weeks if therapy was mitomycin C and/or nitrosoureas), or within 5 half-lives of&#xD;
             the agent (if half-life is known and it is shorter) before the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          5. Radiation therapy within 2 weeks before first dose of any study treatment or&#xD;
             unresolved (NCI CTCAE v5.0 Grade &gt; 1) toxicity from previous radiotherapy&#xD;
&#xD;
          6. Clinically significant cardiovascular disease&#xD;
&#xD;
          7. Major surgery within 4 weeks prior to any study treatment administration&#xD;
&#xD;
          8. Any pulmonary, thyroid, renal, hepatic severe/uncontrolled concurrent medical disease&#xD;
             that in the opinion of the Investigator could cause unacceptable safety risks or&#xD;
             compromise compliance with the protocol&#xD;
&#xD;
          9. Active uncontrolled viral, fungal, or bacterial infection requiring systematic therapy&#xD;
             within 14 days prior to first dose of study treatment.&#xD;
&#xD;
         10. Known history of testing positive for human immunodeficiency virus (HIV), and/or&#xD;
             positive test for Hepatitis B virus surface antigen (HBsAg) and/or positive Hep C&#xD;
             antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA)&#xD;
             indicating acute or chronic infection.&#xD;
&#xD;
         11. Autoimmune disease requiring therapy; immunodeficiency, or any disease process&#xD;
             requiring systemic immunosuppressive therapy&#xD;
&#xD;
         12. A serious nonmalignant disease that could compromise protocol objectives in the&#xD;
             opinion of the Investigator and/or the Sponsor&#xD;
&#xD;
         13. Any other condition that, in the opinion of the Investigator, would prohibit the&#xD;
             subject from participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven S. Cha, MD</last_name>
    <role>Study Director</role>
    <affiliation>NKGen Biotech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NKGen Biotech, Inc.</last_name>
    <phone>9493966830</phone>
    <email>trials@nkgenbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez</last_name>
      <phone>323-865-0212</phone>
      <email>Xiomara.Menendez@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lorraine Martinez</last_name>
      <phone>(323) 865 0966</phone>
      <email>Lorraine.Martinez@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR Positive</keyword>
  <keyword>EGFR</keyword>
  <keyword>EGFR+</keyword>
  <keyword>AFM24</keyword>
  <keyword>SNK01</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Refractory</keyword>
  <keyword>Metastatic</keyword>
  <keyword>NSCLC</keyword>
  <keyword>SCCHN</keyword>
  <keyword>NK cells</keyword>
  <keyword>Natural killer cell</keyword>
  <keyword>IgG1</keyword>
  <keyword>antibody</keyword>
  <keyword>CD16A</keyword>
  <keyword>ADCC</keyword>
  <keyword>ADCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

